Morgan Stanley’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-4,292,951
| Closed | -$38.8M | – | 8517 |
|
|
2025
Q4 | $38.8M | Buy |
4,292,951
+4,049,194
| +1,661% | +$30.3M | ﹤0.01% | 2333 |
|
|
2025
Q3 | $758K | Sell |
243,757
-277,261
| -53% | -$735K | ﹤0.01% | 5296 |
|
|
2025
Q2 | $1.11M | Sell |
521,018
-355,143
| -41% | -$574K | ﹤0.01% | 5039 |
|
|
2025
Q1 | $1.01M | Sell |
876,161
-1,634,715
| -65% | -$2.81M | ﹤0.01% | 4996 |
|
|
2024
Q4 | $5.5M | Buy |
2,510,876
+2,178,199
| +655% | +$4.94M | ﹤0.01% | 3916 |
|
|
2024
Q3 | $725K | Sell |
332,677
-298,100
| -47% | -$685K | ﹤0.01% | 5227 |
|
|
2024
Q2 | $1.46M | Sell |
630,777
-703,561
| -53% | -$2.92M | ﹤0.01% | 4759 |
|
|
2024
Q1 | $7.34M | Sell |
1,334,338
-2,495,714
| -65% | -$11.4M | ﹤0.01% | 3585 |
|
|
2023
Q4 | $9.46M | Buy |
3,830,052
+3,545,945
| +1,248% | +$33.7M | ﹤0.01% | 3960 |
|
|
2023
Q3 | $9.87M | Sell |
284,107
-230,184
| -45% | -$7.96M | ﹤0.01% | 3141 |
|
|
2023
Q2 | $16.9M | Sell |
514,291
-81,585
| -14% | -$2.81M | ﹤0.01% | 2641 |
|
|
2023
Q1 | $20M | Buy |
595,876
+476,662
| +400% | +$18.5M | ﹤0.01% | 2426 |
|
|
2022
Q4 | $3.91M | Buy |
119,214
+36,449
| +44% | +$1.08M | ﹤0.01% | 3962 |
|
|
2022
Q3 | $2.89M | Buy |
82,765
+63,512
| +330% | +$1.41M | ﹤0.01% | 4160 |
|
|
2022
Q2 | $236K | Buy |
19,253
+12,536
| +187% | +$187K | ﹤0.01% | 5809 |
|
|
2022
Q1 | $91K | Sell |
6,717
-69
| -1% | -$922 | ﹤0.01% | 6368 |
|
|
2021
Q4 | $135K | Buy |
+6,786
| New | +$129K | ﹤0.01% | 6270 |
|
Other funds holding VTYX
Morgan Stanley's VTYX Position: Q1 2026 in Review
Morgan Stanley sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 4,292,951 shares — an estimated $38.8M sold.
Morgan Stanley first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $38.8M in Q4 2025. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Morgan Stanley reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 4,292,951 Ventyx Biosciences shares in Q1 2026, an estimated $38.8M.
- Morgan Stanley first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Morgan Stanley's Ventyx Biosciences position peaked at $38.8M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.